Genmab | GEN - Beneficio Bruto En Ventas

Precio De Mercado
1,645.00
Cambio Diario
-35.00 -2.08%
Mensual
-11.25%
Anual
19.94%
Q1 Expectativa
1,614.31




Beneficio Bruto En Ventas Cambio Fecha
Agios Pharmaceuticals USD 18.09M 6.89M 2025-12
Almirall EUR 429.87M 180.02M 2025-12
Amarin USD 23.17M 961K 2025-12
Amgen USD 6.48B 307M 2025-09
argenx SE USD 1.14B 118.49M 2025-12
AstraZeneca USD 12.39B 5M 2025-12
Bayer EUR 5.35B 1.02B 2025-09
BioMarin Pharmaceutical USD 713.01M 81.81M 2025-12
Demant DKK 8.82B 277M 2025-12
Exelixis USD 572.18M 7M 2025-12
Fresenius Medical Care EUR 1.39B 147M 2025-12
Galapagos EUR -13.57M 74.82M 2025-09
Genmab DKK 868M 195M 2025-06
GlaxoSmithKline GBP 6.18B 106M 2025-12
GN Store Nord DKK 2.5B 344M 2025-12
GRIFOLS EUR 743.8M 49.13M 2025-06
Hikma Pharmaceutical USD 362.5M 329.5M 2025-06
Insmed USD 217.69M 106.25M 2025-12
Lonza CHF 1.29B 248M 2025-06
Merck EUR 2.96B 252M 2025-12
Novartis USD 10.82B 695M 2025-09
Regeneron Pharmaceuticals USD 3.3B 67M 2025-12
Roche Holding CHF 22.09B 10.04B 2025-12
Sanofi EUR 8.45B 1.31B 2025-12
UCB EUR 2.46B 520M 2024-12